CRDF
Income statement / Annual
Last year (2024), Cardiff Oncology, Inc.'s total revenue was $683.00 K,
an increase of 39.96% from the previous year.
In 2024, Cardiff Oncology, Inc.'s net income was -$45.43 M.
See Cardiff Oncology, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$683.00 K |
$488.00 K |
$386.00 K |
$359.00 K |
$366.00 K |
$244.63 K |
$378.00 K |
$505.00 K |
$381.00 K |
$313.00 K |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$597.00 K
|
$1.81 M
|
$1.73 M
|
$629.00 K
|
| Gross Profit |
$683.00 K
|
$488.00 K
|
$386.00 K
|
$359.00 K
|
$366.00 K
|
$244.63 K
|
-$219.00 K
|
-$1.31 M
|
-$1.35 M
|
-$316.00 K
|
| Gross Profit Ratio |
1
|
1
|
1
|
1
|
1
|
1
|
-0.58
|
-2.59
|
-3.54
|
-1.01
|
| Research and Development Expenses |
$36.85 M
|
$32.86 M
|
$27.11 M
|
$17.38 M
|
$11.24 M
|
$11.16 M
|
$8.16 M
|
$7.88 M
|
$15.01 M
|
$10.59 M
|
| General & Administrative Expenses |
$12.48 M
|
$13.04 M
|
$13.18 M
|
$11.84 M
|
$8.22 M
|
$5.76 M
|
$8.01 M
|
$11.50 M
|
$11.48 M
|
$7.92 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$417.00
|
$2.74 M
|
$11.52 M
|
$6.44 M
|
| Selling, General & Administrative Expenses |
$12.48 M
|
$13.04 M
|
$13.18 M
|
$11.84 M
|
$8.22 M
|
$5.76 M
|
$8.01 M
|
$14.23 M
|
$23.00 M
|
$14.36 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$170.00 K
|
-$145.00 K
|
-$3.00 K
|
| Operating Expenses |
$49.33 M
|
$45.90 M
|
$40.29 M
|
$29.21 M
|
$19.45 M
|
$16.92 M
|
$16.17 M
|
$22.12 M
|
$38.01 M
|
$24.96 M
|
| Cost And Expenses |
$49.33 M
|
$45.90 M
|
$40.29 M
|
$29.21 M
|
$19.45 M
|
$16.92 M
|
$16.77 M
|
$23.93 M
|
$39.74 M
|
$25.59 M
|
| Interest Income |
$3.26 M
|
$4.07 M
|
$1.58 M
|
$264.00 K
|
$90.00 K
|
$234.17 K
|
$219.43 K
|
$147.88 K
|
$0.00
|
$57.26 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.00 K
|
$0.00
|
$25.41 K
|
$1.03 M
|
$1.38 M
|
$1.53 M
|
| Depreciation & Amortization |
$404.00 K
|
$398.00 K
|
$236.00 K
|
$451.00 K
|
$466.00 K
|
$494.23 K
|
$736.09 K
|
$1.05 M
|
$1.07 M
|
$378.71 K
|
| EBITDA |
-$48.25 M |
-$45.01 M |
-$39.67 M |
-$28.40 M |
-$18.84 M |
-$15.92 M |
-$15.70 M |
-$22.82 M |
-$36.76 M |
-$24.89 M |
| EBITDA Ratio |
-70.64
|
-92.24
|
-102.76
|
-79.12
|
-51.47
|
-65.08
|
-41.53
|
-45.19
|
-96.48
|
-79.54
|
| Operating Income Ratio |
-71.23
|
-93.06
|
-103.37
|
-80.38
|
-52.15
|
-68.18
|
-45.11
|
-50.69
|
-105.37
|
-80.75
|
| Total Other Income/Expenses Net |
$3.22 M
|
$3.97 M
|
$1.20 M
|
$564.00 K
|
-$221.00 K
|
$264.34 K
|
-$72.45 K
|
$689.05 K
|
$941.89 K
|
-$2.20 M
|
| Income Before Tax |
-$45.43 M
|
-$41.44 M
|
-$38.70 M
|
-$28.29 M
|
-$19.31 M
|
-$16.41 M
|
-$16.46 M
|
-$24.91 M
|
-$39.20 M
|
-$27.47 M
|
| Income Before Tax Ratio |
-66.52
|
-84.92
|
-100.27
|
-78.81
|
-52.75
|
-67.1
|
-43.55
|
-49.32
|
-102.9
|
-87.77
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$617.64 K
|
$716.00 K
|
-$296.00 K
|
$1.82 M
|
| Net Income |
-$45.43 M
|
-$41.44 M
|
-$38.70 M
|
-$28.29 M
|
-$19.31 M
|
-$16.41 M
|
-$16.46 M
|
-$24.91 M
|
-$39.20 M
|
-$27.47 M
|
| Net Income Ratio |
-66.52
|
-84.92
|
-100.27
|
-78.81
|
-52.75
|
-67.1
|
-43.55
|
-49.32
|
-102.9
|
-87.77
|
| EPS |
-0.95 |
-0.93 |
-0.89 |
-0.73 |
-1.08 |
-2.7 |
-7.06 |
-51.71 |
-93.54 |
-75.49 |
| EPS Diluted |
-0.95 |
-0.93 |
-0.89 |
-0.73 |
-1.08 |
-2.7 |
-7.06 |
-51.71 |
-93.22 |
-74.77 |
| Weighted Average Shares Out |
$47.65 M
|
$44.68 M
|
$43.60 M
|
$39.03 M
|
$20.88 M
|
$5.97 M
|
$2.33 M
|
$481.67 K
|
$419.10 K
|
$363.92 K
|
| Weighted Average Shares Out Diluted |
$47.65 M
|
$44.68 M
|
$43.60 M
|
$39.03 M
|
$20.88 M
|
$5.97 M
|
$2.33 M
|
$481.67 K
|
$420.57 K
|
$367.39 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
